Combinating Fingolimod With Alteplase Bridging With Mechanical Thrombectomy in Acute Ischemic Stroke
Status:
Withdrawn
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
Proof-of concept clinical trials have indicated that the sphingosine-1-phosphate receptor
modulator fingolimod may be efficacious in attenuating brain inflammation and improving
clinical outcomes in patients with AIS as a single therapy beyond 4.5 hours of disease onset,
or in combination with alteplase within 4.5 hours of disease onset. So in this study the
investigators try to determine whether the addition of fingolimod, administered within 6
hours after the onset of symptoms in patients receiving alteplase bridging with mechanical
thrombectomy, improves radiologic and clinical outcomes.
Phase:
Phase 2
Details
Lead Sponsor:
Second Affiliated Hospital, School of Medicine, Zhejiang University
Collaborators:
Huzhou Center Hospital Jiaxing People's Hospital Jiaxing Second Hospital Jinhua Center Hospital Shaoxing People's Hospital Taizhou Hospital